TD Securities analyst Derek Lessard initiated coverage of Cannara Biotech (LOVFF) with a Buy rating and C$3.25 price target calling it the firm’s “top pure-play recreational Canadian LP pick.” Cannara is “an industry trendsetter with an obsessiveness for innovation,” which has led to strong customer acquisition, notes the analyst, who cites the recent launch of vapes in Quebec as a main driver of the firm’s 20% forecast sales growth in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LOVFF:
- Cannara Biotech Schedules Investor Webcast to Highlight Cannabis Operations
- Cannara Biotech Secures C$6.3 Million Premium Private Placement from Phoenician Capital
- Cannara Biotech prices 3M shares at C$2.10 in private placement
- Cannara Biotech Secures Conditional TSX Approval in Strategic Uplisting Move
- Cannara Biotech announces conditional approval to list on TSX